Q1 Earnings Forecast for Quantum-Si Issued By HC Wainwright

Quantum-Si Incorporated (NASDAQ:QSI) – Stock analysts at HC Wainwright issued their Q1 2027 earnings per share (EPS) estimates for shares of Quantum-Si in a research note issued on Monday, May 11th. HC Wainwright analyst S. Ramakanth anticipates that the company will post earnings per share of ($0.13) for the quarter. The consensus estimate for Quantum-Si’s current full-year earnings is ($0.50) per share. HC Wainwright also issued estimates for Quantum-Si’s Q2 2027 earnings at ($0.12) EPS, Q3 2027 earnings at ($0.12) EPS and Q4 2027 earnings at ($0.11) EPS.

Quantum-Si (NASDAQ:QSI) last issued its earnings results on Thursday, May 7th. The company reported ($0.10) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.12) by $0.02. Quantum-Si had a negative return on equity of 46.05% and a negative net margin of 5,605.88%.The company had revenue of $0.26 million for the quarter, compared to analysts’ expectations of $0.30 million.

A number of other equities analysts have also recently issued reports on QSI. Weiss Ratings reiterated a “sell (d-)” rating on shares of Quantum-Si in a report on Friday, March 27th. Canaccord Genuity Group cut their target price on Quantum-Si from $1.50 to $1.00 and set a “hold” rating on the stock in a report on Wednesday, March 4th. Two equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat, Quantum-Si has an average rating of “Hold” and an average price target of $3.25.

Quantum-Si Stock Up 1.7%

Shares of QSI opened at $0.92 on Tuesday. Quantum-Si has a 12-month low of $0.69 and a 12-month high of $3.10. The business’s fifty day moving average is $0.89 and its 200 day moving average is $1.18. The stock has a market cap of $199.54 million, a P/E ratio of -1.81 and a beta of 3.15.

Insider Buying and Selling

In other Quantum-Si news, CFO Jeffry R. Keyes sold 37,382 shares of the firm’s stock in a transaction on Monday, April 20th. The stock was sold at an average price of $1.01, for a total transaction of $37,755.82. Following the transaction, the chief financial officer directly owned 1,769,963 shares in the company, valued at approximately $1,787,662.63. This trade represents a 2.07% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Paula Dowdy acquired 109,890 shares of the company’s stock in a transaction on Thursday, March 5th. The shares were bought at an average price of $0.95 per share, for a total transaction of $104,395.50. Following the completion of the purchase, the director owned 269,107 shares in the company, valued at approximately $255,651.65. This represents a 69.02% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Insiders have sold a total of 212,904 shares of company stock valued at $205,021 in the last 90 days. Insiders own 22.04% of the company’s stock.

Hedge Funds Weigh In On Quantum-Si

Large investors have recently bought and sold shares of the stock. Prudential Financial Inc. bought a new position in Quantum-Si during the 2nd quarter valued at $25,000. Curbstone Financial Management Corp bought a new position in Quantum-Si during the 4th quarter valued at $26,000. Capital Investment Advisory Services LLC lifted its stake in Quantum-Si by 100.0% during the 3rd quarter. Capital Investment Advisory Services LLC now owns 20,000 shares of the company’s stock valued at $28,000 after acquiring an additional 10,000 shares in the last quarter. Leonteq Securities AG bought a new stake in shares of Quantum-Si during the 4th quarter worth $28,000. Finally, Cerity Partners LLC bought a new stake in shares of Quantum-Si during the 2nd quarter worth $29,000. 39.90% of the stock is currently owned by institutional investors.

Quantum-Si Company Profile

Quantum-Si Inc is a life sciences instrumentation company headquartered in Guilford, Connecticut, developing next-generation proteomics solutions based on semiconductor sequencing technology. The company’s core offering centers on a proprietary single-molecule protein sequencing platform that uses a silicon-based sensor chip to convert protein data into digital signals. This approach is designed to deliver high sensitivity, single-amino-acid resolution and deep proteome coverage while potentially reducing cost and complexity compared to traditional mass spectrometry methods.

Quantum-Si’s product roadmap includes the development and commercialization of an integrated system comprising instruments, consumable reagents and proprietary data analysis software.